SCHEMBL4887884

SCHEMBL4887884

Cc1cc(O)ccc1-c1c(C)c(C(=O)O)cn1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 8/20 0.44
HSD17B10 Q99714 1/20 0.42
HSD17B1 P14061 1/20 0.42
MYC P01106 1/20 0.42
PTPN1 P18031 1/20 0.42
ESR1 P03372 7/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
TSHR P16473 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891845 0.81 NOTUM (0.37) HSD17B10MYCCA9ALDH1A1MEN1
SCHEMBL4892927 0.80 MYC (0.49) HSD17B10MYCALDH1A1PTGS2MEN1
SCHEMBL16456753 0.78 NR1H4 (0.48) ESR2HSD17B10HSD17B1ESR1HCAR2
SCHEMBL4639358 0.77 S1PR1 (0.48) ALDH1A1MEN1KMT2A
SCHEMBL4896916 0.76 MCL1 (0.41) MYCALDH1A1MEN1MAPTKMT2A
SCHEMBL2439018 0.75 NR3C2 (0.50) ALDH1A1PTGS2MEN1MAPTKMT2A
SCHEMBL9647767 0.74 CA12 (0.52) ESR2HSD17B10HSD17B1MYCPTPN1
SCHEMBL4639687 0.73 MYC (0.49) HSD17B10MYCALDH1A1PTGS2TSHR
SCHEMBL2433825 0.71 KMT2A (0.48) HSD17B10MYCPTPN1CA12CA1
SCHEMBL2007723 0.71 KMT2A (0.55) MYCPTPN1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US claimed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ESR2 339/4885HSD17B10 2768/4885HSD17B1 1535/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ESR2 339/4885HSD17B10 2768/4885HSD17B1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.